文献速递细菌感染、耐药与抗菌药物结核与非结核分枝杆菌艾滋病与性传播感染

2000年以来涉及中低收入国家的超国家抗菌药物耐药监测网络清单

An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该研究检索了2000年以来涉及中低收入国家(LMIC)并开展抗菌药物耐药(AMR)监测的超国家网络,评估其组织、方法、影响与挑战。自2000年以来共创建72个涉及LMIC的细菌、真菌、HIV、结核和疟疾AMR监测超国家网络,其中34个仍在运行;网络持续时间中位数为6年(范围1-70),纳入LMIC数量中位数为8个(范围1-67)。网络面临的最大挑战是在各LMIC实现高覆盖率和遵循推荐报告频率,在LMIC获取高质量、有代表性的监测数据具有挑战性。

要点

  • 自2000年以来共创建72个涉及LMIC的AMR监测超国家网络,其中34个仍在运行。
  • 网络持续时间中位数为6年(范围1-70),纳入LMIC数量中位数为8个(范围1-67)。
  • 最大挑战是在各LMIC实现高覆盖率和遵循推荐报告频率,获取高质量代表性数据困难。

核心结论

  • 自2000年以来共创建72个涉及LMIC的AMR监测超国家网络,其中34个仍在运行。
  • 在LMIC获取高质量、有代表性的监测数据具有挑战性。
  • 作者认为,过往经验提示许多LMIC可能需要补充主动监测方法才能获得有代表性、临床相关且有意义的数捤。
  • 作者认为,维护最新的网络登记目录将促进更协调的监测方法。

研究设计与样本

  • 研究检索了开展LMIC抗菌药物耐药监测的超国家网络,并评估其组织、方法、影响与挑战。
  • 自2000年以来共创建72个涉及LMIC的细菌、真菌、HIV、结核和疟疾AMR监测超国家网络,其中34个仍在运行。

主要发现

  • 网络持续时间中位数为6年(范围1-70),纳入LMIC数量中位数为8个(范围1-67)。
  • 网络按类型分为WHO/政府型(n=26)、学术型(n=24)或药企发起型(n=22)。
  • 资金来源多样:30个网络获得公共或WHO资助,25个获得企业资助,13个获得信托或基金会资助,4个由多个来源资助。
  • 结核、疟疾和HIV耐药监测的领先全球规划通过定期主动监测或主动与被动相结合的方式在LMIC收集数据。
  • 网络面临的最大挑战是在各LMIC实现高覆盖率以及遵循推荐报告频率。

关键数值与推荐

  • 抗菌药物耐药监测需要一定水平的实验室基础设施和培训,而这些在LMIC尚未广泛具备。
  • 新生的全球抗菌药物耐药监测系统(GLASS)旨在所有成员国建立被动监测。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Low- and middle-income countries (LMICs) shoulder the bulk of the global burden of infectious diseases and drug resistance. We searched for supranational networks performing antimicrobial resistance (AMR) surveillance in LMICs and assessed their organization, methodology, impacts and challenges. Since 2000, 72 supranational networks for AMR surveillance in bacteria, fungi, HIV, TB and malaria have been created that have involved LMICs, of which 34 are ongoing. The median (range) duration of the networks was 6 years (1-70) and the number of LMICs included was 8 (1-67). Networks were categorized as WHO/governmental (n = 26), academic (n = 24) or pharma initiated (n = 22). Funding sources varied, with 30 networks receiving public or WHO funding, 25 corporate, 13 trust or foundation, and 4 funded from more than one source. The leading global programmes for drug resistance surveillance in TB, malaria and HIV gather data in LMICs through periodic active surveillance efforts or combined active and passive approaches. The biggest challenges faced by these networks has been achieving high coverage across LMICs and complying with the recommended frequency of reporting. Obtaining high quality, representative surveillance data in LMICs is challenging. Antibiotic resistance surveillance requires a level of laboratory infrastructure and training that is not widely available in LMICs. The nascent Global Antimicrobial Resistance Surveillance System (GLASS) aims to build up passive surveillance in all member states. Past experience suggests complementary active approaches may be needed in many LMICs if representative, clinically relevant, meaningful data are to be obtained. Maintaining an up-to-date registry of networks would promote a more coordinated approach to surveillance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ashley EA, Recht J, Chua A, et al. An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. J Antimicrob Chemother. 2018. PMID: 29514279. doi:10.1093/jac/dky026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。